Insider Selling: Bicycle Therapeutics plc (NASDAQ:BCYC) CAO Sells 1,750 Shares of Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) CAO Travis Alvin Thompson sold 1,750 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total value of $24,657.50. Following the completion of the sale, the chief accounting officer now directly owns 34,991 shares in the company, valued at approximately $493,023.19. This represents a 4.76 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Travis Alvin Thompson also recently made the following trade(s):

• On Monday, January 6th, Travis Alvin Thompson sold 2,686 shares of Bicycle Therapeutics stock. The shares were sold at an average price of $15.00, for a total value of $40,290.00.
• On Monday, November 11th, Travis Alvin Thompson sold 6,256 shares of Bicycle Therapeutics stock. The stock was sold at an average price of $25.11, for a total transaction of $157,088.16.

Bicycle Therapeutics Trading Down 0.1 %

Bicycle Therapeutics stock traded down $0.01 during mid-day trading on Monday, hitting $14.88. The stock had a trading volume of 289,310 shares, compared to its average volume of 435,603. The stock has a 50-day simple moving average of $19.27 and a two-hundred day simple moving average of $21.86. The stock has a market capitalization of $1.03 billion, a PE ratio of -4.52 and a beta of 0.92. Bicycle Therapeutics plc has a 12 month low of $12.17 and a 12 month high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.74) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.04. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The company had revenue of $2.68 million during the quarter, compared to analysts’ expectations of $6.82 million. During the same quarter in the previous year, the company earned ($1.26) EPS. Bicycle Therapeutics’s revenue was down 50.0% on a year-over-year basis. Sell-side analysts expect that Bicycle Therapeutics plc will post -3.05 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have weighed in on BCYC shares. JMP Securities decreased their price objective on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a research note on Wednesday, December 18th. Cantor Fitzgerald restated an “overweight” rating on shares of Bicycle Therapeutics in a research report on Monday, September 9th. Royal Bank of Canada reiterated an “outperform” rating and issued a $35.00 price objective on shares of Bicycle Therapeutics in a research report on Friday, November 1st. Stephens started coverage on Bicycle Therapeutics in a report on Friday, November 8th. They set an “equal weight” rating and a $25.00 target price on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $38.00 price target on shares of Bicycle Therapeutics in a report on Thursday, October 31st. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $35.25.

Hedge Funds Weigh In On Bicycle Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Assetmark Inc. acquired a new stake in Bicycle Therapeutics in the third quarter worth $34,000. GAMMA Investing LLC raised its holdings in shares of Bicycle Therapeutics by 105.1% during the third quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock worth $46,000 after acquiring an additional 1,038 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Bicycle Therapeutics by 69.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock valued at $162,000 after purchasing an additional 2,918 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Bicycle Therapeutics by 26.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock valued at $191,000 after acquiring an additional 1,782 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Bicycle Therapeutics during the 2nd quarter worth approximately $206,000. Institutional investors and hedge funds own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.